The tweet was deleted by the author.
But we saved everything 🙂.
Monte Rosa Therapeutics draws attention to a recent Bloomberg feature exploring the potential of molecular glue degraders for targeting disease-driving proteins previously considered undruggable.
The article, which includes perspectives from Monte Rosa Therapeutics, also credits journalist Robert Langreth for in-depth reporting. The rise of these next-generation molecules could represent a breakthrough in drug discovery, with industry experts highlighting their promise for tackling complex diseases.
Monte Rosa Therapeutics recently announced plans to detail its research on molecular glue degraders and cereblon at an Endpoints webinar scheduled for May 12. The company was previously recognized by IDEA Pharma, earning Disruptive Pioneer status for its work advancing MGD drug development, according to a recent award listing. These developments come as the field draws heightened attention from industry and media.